Filing Details

Accession Number:
0001181431-14-022659
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-04 16:29:17
Reporting Period:
2014-06-02
Filing Date:
2014-06-04
Accepted Time:
2014-06-04 16:29:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1375151 Zogenix Inc. ZGNX Pharmaceutical Preparations (2834) 205300780
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1250252 D Ann Rhoads C/O Zogenix, Inc.
12400 High Bluff Dr., Suite 650
San Diego CA 92130
Evp, Cfo, Treasurer & Sec. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-06-02 17,746 $2.10 471,463 No 4 S Direct
Common Stock Disposition 2014-06-03 1,464 $2.03 469,999 No 4 S Direct
Common Stock Disposition 2014-06-03 19 $2.00 469,980 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. This sale of shares of common stock underlying vested restricted stock units was effected by the reporting person to cover the taxes payable upon the vesting of 46,000 restricted stock units on June 1, 2014.
  2. Reflects the weighted average sale price of the shares sold. These shares were sold in multiple transactions at prices ranging from $2.03 to $2.27. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Reflects the weighted average sale price of the shares sold. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.